Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Micromet has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance the development of blinatumomab, used to cure acute lymphoblastic leukemia (ALL) and other sub-types of lymphoma.
Subscribe to our email newsletter
Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body’s T cells to kill cancer cells.
As per the deal, the NCI and Micromet will work on a series of clinical trials to evaluate the safety and efficacy of blinatumomab in patients with B-cell derived hematologic malignancies.
The initial NCI-sponsored studies will explore blinatumomab’s utility as the first-line treatment for patients newly diagnosed with ALL, older patients with ALL, and patients with Waldenstrom’s macroglobulinemia.
Micromet senior vice president and chief medical officer said the partnership would help them explore blinatumomab’s clinical potential across a wide range of blood cancers.